Physician profile
Dean Karnaze
NPI 1346276359
$2,556.69
in general payments reported to CMS, 2019-2025
25 companies · $74.95 in 2025
The $74.95 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $142 · 2021: $355 · 2022: $351 · 2023: $225 · 2024: $458 · 2025: $74.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,075.81 | 2019-2025 | Mavenclad, Mavenclad |
| Novo Nordisk INC | $228.51 | 2023-2024 | |
| Genzyme Corporation | $184.24 | 2019 | |
| Amneal Pharmaceuticals LLC | $133.29 | 2019 | |
| Eisai INC. | $123.71 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $108.02 | 2021 | |
| Lilly USA, LLC | $91.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $67.86 | 2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $55.53 | 2023-2024 | Ultomiris |
| Biogen, INC. | $51.06 | 2019 | |
| Abbvie INC. | $48.06 | 2022 | |
| Vertical Pharmaceuticals, LLC | $32.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.50 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $26.43 | 2022 | |
| Ucb, INC. | $25.89 | 2019 | |
| Genentech USA, INC. | $25.84 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.46 | 2019 | |
| Mdd US Operations, LLC | $24.01 | 2019 | |
| Acadia Pharmaceuticals INC | $22.10 | 2019 | |
| Greenwich Biosciences, INC. | $20.98 | 2019 | |
| Neurocrine Biosciences, INC. | $17.18 | 2019 | |
| Acorda Therapeutics, INC | $13.14 | 2019 | |
| Pfizer INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Karnaze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.